Novelna

Executive Summary

Novelna is a San Francisco-based biotechnology company founded in 2020 that is pioneering next-generation diagnostics for the early detection of cancer and chronic diseases. Leveraging an AI-enabled proteomics platform, the company discovers and validates novel protein biomarkers to develop highly accurate, accessible, and affordable blood- and urine-based tests. Its mission is to democratize early disease detection, transforming it from a privilege into a universal right. Novelna's approach combines advanced machine learning with proteomic analysis to identify patterns indicative of disease at their earliest, most treatable stages. While still in the early-stage development phase, the company's technology has the potential to significantly improve patient outcomes and reduce healthcare costs by enabling earlier intervention. Novelna operates in the competitive liquid biopsy space, but its focus on proteomics differentiates it from many peers that rely primarily on genomics or epigenomics. The company's ability to validate its biomarkers in large clinical cohorts and secure strategic partnerships will be critical to its success. Given its early stage, Novelna has not yet disclosed specific funding rounds or regulatory milestones, but its foundational research and platform technology position it well for future growth.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement70% success
• Q2 2027Initial Clinical Validation Data from Multi-Cancer Early Detection Study50% success
• H1 2027Strategic Partnership with Major Diagnostics or Pharma Company40% success